Luo ZG - Search Results

1

Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma.

Liu X, Hong XN, Gu YJ, Wang BY, Luo ZG, Cao J. Liu X, et al. Among authors: luo zg. Leuk Lymphoma. 2008 Sep;49(9):1778-83. doi: 10.1080/10428190802270886. Leuk Lymphoma. 2008. PMID: 18798110

2

Lack of association between methylenetetrahydrofolate reductase gene A1298C polymorphism and breast cancer susceptibility.

Qiu LX, Zhang J, Li WH, Zhang QL, Yu H, Wang BY, Wang LP, Wang JL, Wang HJ, Liu XJ, Luo ZG, Wu XH. Qiu LX, et al. Among authors: luo zg. Mol Biol Rep. 2011 Apr;38(4):2295-9. doi: 10.1007/s11033-010-0361-2. Epub 2010 Nov 5. Mol Biol Rep. 2011. PMID: 21052845

3

Advanced breast angiosarcoma completely responding to gemcitabine-containing chemotherapy.

Luo ZG, Wang Q, Peng W, Hu XC, Hong XN. Luo ZG, et al. Breast Care (Basel). 2012 Oct;7(5):414-6. doi: 10.1159/000343614. Breast Care (Basel). 2012. PMID: 24647783 Free PMC article.

4

A Phase II Study of Gemcitabine, Vincristine, and Cisplatin As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma.

Luo Z, Zhang X, Peng W, Wu X, Wang H, Yu H, Wang J, Chang J, Hong X. Luo Z, et al. Medicine (Baltimore). 2015 Oct;94(43):e1777. doi: 10.1097/MD.0000000000001777. Medicine (Baltimore). 2015. PMID: 26512574 Free PMC article. Clinical Trial.

5

Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study.

Ji D, Li Q, Cao J, Guo Y, Lv F, Liu X, Wang B, Wang L, Luo Z, Chang J, Wu X, Hong X. Ji D, et al. Oncotarget. 2016 May 31;7(22):33331-9. doi: 10.18632/oncotarget.8973. Oncotarget. 2016. PMID: 27129176 Free PMC article. Clinical Trial.

6

Significance of glucocorticoid receptor expression in patients with non-small cell lung cancer treated with pemetrexed-based chemotherapy.

Zhao XM, Zhao J, Wu XH, Luo ZG, Wang HJ, Yu H, Chang JH, Wang JL. Zhao XM, et al. Among authors: luo zg. Cancer Chemother Pharmacol. 2017 Oct;80(4):851-860. doi: 10.1007/s00280-017-3399-1. Epub 2017 Jul 28. Cancer Chemother Pharmacol. 2017. PMID: 28755014

7

Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis.

Liu X, Wang H, Wu X, Hong X, Luo Z. Liu X, et al. Invest New Drugs. 2018 Feb;36(1):114-120. doi: 10.1007/s10637-017-0542-0. Epub 2017 Nov 23. Invest New Drugs. 2018. PMID: 29170886 Clinical Trial.

8

Bone metastasis pattern of cancer patients with bone metastasis but no visceral metastasis.

Zhu M, Liu X, Qu Y, Hu S, Zhang Y, Li W, Zhou X, Yang H, Zhou L, Wang Q, Hou Y, Chen Y, Wang Y, Wang Y, Lu Z, Luo Z, Hu X. Zhu M, et al. J Bone Oncol. 2019 Jan 23;15:100219. doi: 10.1016/j.jbo.2019.100219. eCollection 2019 Apr. J Bone Oncol. 2019. PMID: 30740298 Free PMC article.

9

DEPDC1B knockdown inhibits the development of malignant melanoma through suppressing cell proliferation and inducing cell apoptosis.

Xu Y, Sun W, Zheng B, Liu X, Luo Z, Kong Y, Xu M, Chen Y. Xu Y, et al. Exp Cell Res. 2019 Jun 1;379(1):48-54. doi: 10.1016/j.yexcr.2019.03.021. Epub 2019 Mar 14. Exp Cell Res. 2019. PMID: 30880030

10

Chondroitin polymerizing factor (CHPF) promotes development of malignant melanoma through regulation of CDK1.

Sun W, Zhao F, Xu Y, Huang K, Guo X, Zheng B, Liu X, Luo Z, Kong Y, Xu M, Schadendorf D, Chen Y. Sun W, et al. Cell Death Dis. 2020 Jul 1;11(7):496. doi: 10.1038/s41419-020-2526-9. Cell Death Dis. 2020. PMID: 32612115 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

181 results

Search Page

Filters